Gene: GLA ×
Source: INFERRED ×
Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs104894827
rs104894827
GLA ; RPL36A-HNRNPH2
A 0.800 CausalMutation CLINVAR Fabry disease: six gene rearrangements and an exonic point mutation in the alpha-galactosidase gene. 2539398

1989
dbSNP: rs104894827
rs104894827
GLA ; RPL36A-HNRNPH2
A 0.800 CausalMutation CLINVAR What lies beneath: Fabry nephropathy in a female patient with severe cerebrovascular disease. 23537685

2013
dbSNP: rs104894827
rs104894827
GLA ; RPL36A-HNRNPH2
A 0.800 CausalMutation CLINVAR High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population. 20031620

2009
dbSNP: rs104894827
rs104894827
GLA ; RPL36A-HNRNPH2
A 0.800 CausalMutation CLINVAR Fabry disease: a new approach for the screening of females in high-risk groups. 24582695

2014
dbSNP: rs104894827
rs104894827
GLA ; RPL36A-HNRNPH2
A 0.800 CausalMutation CLINVAR New mutations in the GLA gene in Brazilian families with Fabry disease. 22551898

2012
dbSNP: rs104894827
rs104894827
GLA ; RPL36A-HNRNPH2
A 0.800 CausalMutation CLINVAR Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples. 27532257

2017
dbSNP: rs104894827
rs104894827
GLA ; RPL36A-HNRNPH2
A 0.800 CausalMutation CLINVAR α-Galactosidase aggregation is a determinant of pharmacological chaperone efficacy on Fabry disease mutants. 22773828

2012
dbSNP: rs104894827
rs104894827
GLA ; RPL36A-HNRNPH2
A 0.800 CausalMutation CLINVAR Lysosome-associated protein 1 (LAMP-1) and lysosome-associated protein 2 (LAMP-2) in a larger family carrier of Fabry disease. 24334114

2014
dbSNP: rs104894827
rs104894827
GLA ; RPL36A-HNRNPH2
A 0.800 CausalMutation CLINVAR Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity. 25611685

2015
dbSNP: rs104894827
rs104894827
GLA ; RPL36A-HNRNPH2
A 0.800 CausalMutation CLINVAR Mutant alpha-galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity: biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin. 17555407

2007
dbSNP: rs104894827
rs104894827
GLA ; RPL36A-HNRNPH2
A 0.800 CausalMutation CLINVAR A pharmacogenetic approach to identify mutant forms of α-galactosidase A that respond to a pharmacological chaperone for Fabry disease. 21598360

2011
dbSNP: rs104894827
rs104894827
GLA ; RPL36A-HNRNPH2
A 0.800 CausalMutation CLINVAR Molecular damage in Fabry disease: characterization and prediction of alpha-galactosidase A pathological mutations. 25382311

2015
dbSNP: rs104894827
rs104894827
GLA ; RPL36A-HNRNPH2
A 0.800 CausalMutation CLINVAR Screening for pharmacological chaperones in Fabry disease. 17532296

2007
dbSNP: rs104894827
rs104894827
GLA ; RPL36A-HNRNPH2
A 0.800 CausalMutation CLINVAR Functional characterisation of alpha-galactosidase a mutations as a basis for a new classification system in fabry disease. 23935525

2013
dbSNP: rs104894828
rs104894828
GLA ; RPL36A-HNRNPH2
T 0.840 CausalMutation CLINVAR Mutations of the GLA gene in Korean patients with Fabry disease and frequency of the E66Q allele as a functional variant in Korean newborns. 20505683

2010
dbSNP: rs104894828
rs104894828
GLA ; RPL36A-HNRNPH2
T 0.840 CausalMutation CLINVAR Identification of point mutations in the alpha-galactosidase A gene in classical and atypical hemizygotes with Fabry disease. 2171331

1990
dbSNP: rs104894828
rs104894828
GLA ; RPL36A-HNRNPH2
T 0.840 CausalMutation CLINVAR Pharmacological chaperone therapy for Fabry disease. 22241068

2012
dbSNP: rs104894828
rs104894828
GLA ; RPL36A-HNRNPH2
T 0.840 CausalMutation CLINVAR Molecular damage in Fabry disease: characterization and prediction of alpha-galactosidase A pathological mutations. 25382311

2015
dbSNP: rs104894828
rs104894828
GLA ; RPL36A-HNRNPH2
T 0.840 CausalMutation CLINVAR A pharmacogenetic approach to identify mutant forms of α-galactosidase A that respond to a pharmacological chaperone for Fabry disease. 21598360

2011
dbSNP: rs104894828
rs104894828
GLA ; RPL36A-HNRNPH2
T 0.840 CausalMutation CLINVAR Generation and characterization of transgenic mice expressing a human mutant alpha-galactosidase with an R301Q substitution causing a variant form of Fabry disease. 9395081

1997
dbSNP: rs104894828
rs104894828
GLA ; RPL36A-HNRNPH2
T 0.840 CausalMutation CLINVAR Measurement of urinary CDH and CTH by tandem mass spectrometry in patients hemizygous and heterozygous for Fabry disease. 15702404

2005
dbSNP: rs104894828
rs104894828
GLA ; RPL36A-HNRNPH2
T 0.840 CausalMutation CLINVAR Fabry disease: twenty-two novel mutations in the alpha-galactosidase A gene and genotype/phenotype correlations in severely and mildly affected hemizygotes and heterozygotes. 10916280

2000
dbSNP: rs104894828
rs104894828
GLA ; RPL36A-HNRNPH2
T 0.840 CausalMutation CLINVAR Genotype: A Crucial but Not Unique Factor Affecting the Clinical Phenotypes in Fabry Disease. 27560961

2016
dbSNP: rs104894828
rs104894828
GLA ; RPL36A-HNRNPH2
T 0.840 CausalMutation CLINVAR Fabry disease: identification of novel alpha-galactosidase A mutations and molecular carrier detection by use of fluorescent chemical cleavage of mismatches. 10208848

1999
dbSNP: rs104894828
rs104894828
GLA ; RPL36A-HNRNPH2
T 0.840 CausalMutation CLINVAR A new phenotype of Fabry disease with intermediate severity between the classical form and the cardiac variant. 11688386

2001